{"id":60812,"date":"2025-02-19T19:02:37","date_gmt":"2025-02-19T18:02:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/"},"modified":"2025-02-19T19:02:37","modified_gmt":"2025-02-19T18:02:37","slug":"covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/","title":{"rendered":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cBeing included on this prestigious list of TSXV-listed companies is an honor for Covalon,\u201d said Brent Ashton, CEO of Covalon Technologies. \u201cIt\u2019s a testament to the hard work of our entire team in 2024 to create and capture value through our differentiated product portfolios. We are still early in the value creation journey and are very excited for the long-term growth potential for the Company. As we expand our investor base, we remain committed to strengthening relationships with our existing investors in the United States, Canada and beyond.\u201d\n<\/p>\n

\nFor more details on the 2025 TSXV Top 50, please visit www.tsx.com\/venture50<\/a>.\n<\/p>\n

\nTo learn more about Covalon, please visit our website at www.covalon.com<\/a> or contact us at investors@covalon.com<\/a>.\n<\/p>\n

\nAbout Covalon<\/b>\n<\/p>\n

\nCovalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com<\/a>.\n<\/p>\n

\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n<\/p>\n

\nThis news release may contain forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan\u201d, “estimate”, “expect”, “intend”, or variations of such words and phrases or state that certain actions, events, or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cwill\u201d or \u201cwill be taken\u201d, \u201coccur\u201d, or \u201cbe achieved\u201d. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management\u2019s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the \u201cRisks and Uncertainties\u201d section of our management\u2019s discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company\u2019s profile at www.sedarplus.ca<\/a>, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTo learn more about Covalon, please contact:\n<\/p>\n

\nInvestor Relations, Covalon Technologies Ltd.
\n
Email: investors@covalon.com<\/a>
Website: https:\/\/covalon.com\/<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60812","6":"format-standard","7":"category-industry"},"yoast_head":"\nCovalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T18:02:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company\",\"datePublished\":\"2025-02-19T18:02:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/\"},\"wordCount\":568,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250219273028\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/\",\"name\":\"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250219273028\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"datePublished\":\"2025-02-19T18:02:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250219273028\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250219273028\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/","og_locale":"en_US","og_type":"article","og_title":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/","og_site_name":"Pharma Trend","article_published_time":"2025-02-19T18:02:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company","datePublished":"2025-02-19T18:02:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/"},"wordCount":568,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/","url":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/","name":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","datePublished":"2025-02-19T18:02:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250219273028\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/covalon-technologies-ltd-named-as-a-tsx-venture-exchange-2025-top-50-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60812"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60812\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}